Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
CNBC
Read Full Article at CNBC →Ad Slot — In-Article (728x90)
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
This is a summary. For the full story, read the original article at CNBC.
Original source: CNBC